维立志博－Ｂ(09887.HK)公布招股结果，香港公开发售接获3,494.78倍认购，一手(100股)中签率仅0.27%，认购4万股始获稳派一手。按回补机制，公开发售股份已增至1,602.72万股，占发售总数43.48%。国际发售录得40.78倍认购。最终发售价35元，上限定价，集资净额11.79亿元。股份预期周五(25日)挂牌。
生物科技公司维立志博是次拟全球发售3,205.44万股，公开发售原占10%，招股价介乎31.6-35元。包括腾讯(00700.HK) 、易方达基金及Foresight Funds等基石投资者合共认购1,547.45万股。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-07-24 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.